Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis

Lupus

Volumn 6, Issue 5, 1997, Pages 467-473

  Wahl, D G ^a   Guillemin, F ^b   De Maistre, E ^a   Perret, C ^a   Lecompte, T ^a   Thibaut, G ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Anticardiolipin antibodies; Hughes syndrome; Lupus anticoagulant; Systemic lupus erythematosus; Venous thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ARTICLE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

EID: 0030779955     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600510     Document Type: Article

References (32)

1. Gharavi AE, Wilson WA. The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Lupus 1996; 5: 343-344.
2. Alarcon-Segovia D et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-365.
3. Chalmers I, Altman DG (eds). Systematic Reviews. BMJ Publishing Group: London, 1995.
4. Armitage P, Berry G. Statistical Methods in Medical Research. Blackwell Science Ltd: Oxford, 1994.
5. Hasselblad V et al. A survey of current problems in meta-analysis. Discussion from the agency for health care policy and research inter- PORT work group on literature review/meta-analysis. Med Care 1995; 33: 202-220.
6. Cook DJ et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995; 108: 227S-230S.
7. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430.
8. Regan MG, Lackner H, Karpatkin S. Platelet function and coagulation profile in lupus erythematosus. Ann Intern Med 1974; 81: 462-468.
9. Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 1979; 94: 312-323.
10. Gladman DD, Urowitz MB, Tozman EC, Glynn MFX. Haemostatic abnormalities in systemic lupus erythematosus. Q J Med 1983; 52: 424-433.
11. Mintz G, Acevedo-Vazquez E, Gutierrez-Espinosa G, Avelar-Garnica F. Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus. Arthritis Rheum 1984; 27: 539-544.
12. Glueck HI et al. Thrombosis in systemic lupus erythematosus. Arch Intern Med 1985; 145: 1389-1395.
13. Pauzner R, Rosner E, Many A. Circulating anticoagulant in systemic lupus erythematosus: clinical manifestations. Acta Haematol (Basel) 1986; 76: 90-94.
14. Petri M et al. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Arch Intern Med 1987; 106: 524-531.
15. Sturfelt G et al. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 382-388.
16. Manoussakis MN et al. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol 1987; 144: 297-307.
17. Averbuch M, Koifman B, Levo Y. Lupus anticoagulant, thrombosis and thrombocytopenia in systemic lupus erythematosus. Am J Med Sci 1987; 293: 1-5.
18. Derksen RHWM, Bouma BN, Kater L. The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol 1987; 16: 185-192.
19. McHugh NJ et al. Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythematosus. Ann Rheum Dis 1988; 47: 110-115.
20. Kalunian KC et al. Clinical significance of a single test for anticardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85: 602-608.
21. Rowell NR, Tate GM. The lupus anticoagulant in systemic lupus erythematosus. Acta Derm Venereol (Stockh) 1989; 69: 111-115.
22. Ferro D et al. Specificity and sensitivity of diluted aPTT and anticardiolipin antibodies towards thrombosis and miscarriages in patients with systemic lupus erythematosus. Thromb Res 1990; 59: 609-617.
23. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 1990; 74: 319-330.
24. Jouhikamen T et al. Platelet autoantibodies detected by immunoblotting in systemic lupus erythematosus: association with the lupus anticoagulant, and with history of thrombosis and thrombocytopenia. Eur J Haematol 1990; 44: 234-239.
25. Jones HW et al. Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 173- 175.
26. McHugh NJ et al. Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 548-555.
27. Wong KL et al. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 1187-1192.
28. Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993; 32: 568-573.
29. Ghirardello A et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis 1994; 54: 140-142.
30. Metz D et al. Anomalies cardiaques dans le lupus erythémateux disséminé diagnostiquées par échographie doppler. Prévalence et association au syndrome des antiphospholipides. Presse Med 1994, 23: 1797-1802.
31. Ginsberg JS et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98: 379- 383.
32. Horbach DA et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924.